

| | |
|-------------------------|--|
| 1. Record Nr. | UNINA9910877982103321 |
| Titolo | Advances in Novel Formulations for Drug Delivery / / Keservani |
| Pubbl/distr/stampa | , 2023.2 |
| ISBN | 9781394167708 1394167709 9781394167692 1394167695 |
| Descrizione fisica | 1 online resource (576 pages) |
| Disciplina | 615.6 |
| Soggetti | Drug delivery systems |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di bibliografia | Includes bibliographical references and index. |
| Nota di contenuto | Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Part I: Novel Drug Carriers and Therapeutics -- Chapter 1 Nanoarchitected Materials: Their Applications and Present Scenarios in Drug Delivery -- 1.1 Introduction -- 1.2 Liposomes -- 1.3 Nanoparticles -- 1.3.1 Nanoparticles in Drug Delivery -- 1.4 Nanoemulsions -- 1.4.1 Advantages and Shortcomings of Nanoemulsions -- 1.4.2 Application of Nanoemulsion in Drug Delivery -- 1.5 Dendrimers -- 1.5.1 Synthesis of Dendrimers -- 1.5.2 Advantages of Dendrimers -- 1.5.3 Applications of Dendrimers in Drug Delivery -- 1.6 Aquasomes -- 1.6.1 Properties of Aquasomes -- 1.6.2 Application of Aquasomes in Drug Delivery -- 1.7 Nanogel -- 1.7.1 Properties of Nanogels -- 1.7.2 Nanogels in Drug Delivery -- 1.8 Quantum Dots -- 1.8.1 Applications of Quantum Dots in Drug Delivery -- 1.9 Carbon Nanotubes -- 1.9.1 Features of Carbon Nanotubes -- 1.9.2 Carbon Nanotubes in Drug Delivery -- References -- Chapter 2 Nanopharmaceuticals for Drug Delivery -- 2.1 Introduction -- 2.2 What Are Nanopharmaceuticals and What Do They Do? -- 2.3 Nanopharmaceuticals Importance -- 2.4 Nanotechnology -- 2.5 Pharmaceutical Companies and Nanotechnology -- 2.6 Applications and Advantages of Nanopharmaceuticals as Drug Carriers -- 2.7 Characteristics of Nanoparticles in Nanopharmaceuticals -- 2.7.1 Particle Size -- 2.7.2 Surface Properties of Nanoparticles -- |

2.7.3 Drug Loading -- 2.7.4 Drug Release -- 2.8 Targeted Drug Delivery -- 2.9 Types of Nanoparticles -- 2.10 Nanoparticle Preparation Methods -- 2.11 Evaluation of Nanoparticles -- 2.12 Efficiency of Drug Entrapment -- 2.13 Particle Shape -- 2.14 Size of the Particles -- 2.15 Zeta Potential -- 2.16 Rise of Nanopharmaceuticals -- 2.17 Nanopharmaceuticals Approval Regulations (FDA Rules & Regulations) -- 2.18 Conclusions and Prospects for the Future -- References.

Chapter 3 Applications and Prospects of Nanopharmaceuticals Delivery -- 3.1 Introduction -- 3.2 Nanopharmaceuticals -- 3.3 Development of Nanopharmaceuticals -- 3.3.1 From Lab to the Marketplace -- 3.3.2 Techniques -- 3.3.3 Cost -- 3.3.4 Ethics -- 3.3.5 Nanopharmaceuticals Approval Regulations (FDA Rules & Regulations) -- 3.4 Clinical Applications of Nanotechnology -- 3.4.1 Diagnostic Applications -- 3.4.1.1 Detection -- 3.4.1.2 Protein Chips -- 3.4.1.3 Individual Target Probes -- 3.4.1.4 Nanotechnology as a Tool in Imaging -- 3.4.1.5 Sparse Cell Detection -- 3.4.2 Therapeutic Applications -- 3.4.2.1 Surfaces -- 3.4.2.2 Gene Delivery -- 3.4.2.3 Drug Delivery -- 3.4.2.4 Liposomes -- 3.4.2.5 Nanotechnology in Orthopedic Applications -- 3.4.2.6 Nanotechnology in Cardiac Therapy -- 3.4.2.7 Nanotechnology in Dental Care -- 3.4.2.8 Biomolecular Engineering -- 3.4.2.9 Biopharmaceuticals -- 3.5 Nanopharmaceuticals Delivery-Recent Applications -- 3.5.1 Nanoparticulate Systems for Vaccine -- 3.5.1.1 Polyanhydride-Based NPs -- 3.5.1.2 Biodegradable Synthetic PLGA NPs -- 3.5.1.3 Liposome-Based NPs -- 3.5.1.4 Polysaccharide-Based NPs -- 3.5.2 Chemotherapy -- 3.5.2.1 Increasing the Concentration of Chemotherapeutic Agents in Tumor Tissue -- 3.5.3 Drug/Gene Delivery -- 3.5.3.1 Nanoparticles Used in Drug Delivery System -- 3.5.3.2 Cellulose -- 3.6 Nanotechnology in Neurodegenerative Disorders Treatment -- 3.7 Future Perspective -- 3.8 Issues with Current Nanopharmaceutical Concepts -- 3.8.1 Large-Scale Manufacturing -- 3.8.2 Biological Challenges -- 3.8.3 Intellectual Property (IP) -- 3.8.4 Biocompatibility and Safety -- 3.8.5 Government Regulations -- 3.9 Conclusion -- References -- Chapter 4 Nanomedicine Regulation and Future Prospects -- 4.1 Introduction -- 4.2 Importance of Regulation of Nanomedicine.

4.3 Regulatory Challenges Faced by Nanomaterial in Medicine -- 4.3.1 Performing Various Functions -- 4.3.2 Nanomedicine Classification Issues -- 4.3.3 Variation in Size of the Particle -- 4.3.4 Manufacturing Process -- 4.3.5 Difficulties to Create CQA -- 4.3.6 Nanotoxicology and Cellular Response -- 4.3.7 Administering Right Doses -- 4.3.8 Pharmacokinetics -- 4.3.9 Developing Guidelines -- 4.4 Nanomedicine Future Aspects -- 4.5 Challenges that Threaten the Future of Nanomedicine -- 4.5.1 Financial Crisis -- 4.5.2 Lack of Confidence -- 4.5.3 Potential Dangers -- 4.5.4 Unsuccessful Patenting -- 4.5.5 Breakdowns in the Pharmaceuticals and Financial Markets -- 4.5.6 Limited Regulation -- 4.6 Future Prospects for Nanomedicine -- 4.6.1 Emerging Nanomaterials -- 4.6.2 Personalized Nanomedicine -- 4.6.3 Nanorobots and Nanodevices -- 4.6.4 Orthopedic Augmentations and Cytocompatibility -- 4.6.5 Cardiology and Nanotechnology -- 4.6.6 Cancer and Nanotechnology -- 4.6.7 NAPT -- 4.6.8 Gene, Protein, Lab-on-a-Chip Devices -- 4.6.9 Polymeric Nanoparticles in Medicine -- References -- Chapter 5 Nanotechnology Application in Drug Delivery for Medicinal Plants -- 5.1 Introduction -- 5.1.1 Nanodrug Delivery Systems (NDDS) -- 5.2 Nanoherbals -- 5.2.1 Cucuma longa (Cucurmin) -- 5.2.2 Gingko biloba -- 5.2.3 Artemisia -- 5.2.4 Silybum marianum-Silymarin -- 5.2.5 Salvia miltiorrhiza (Danshen) -- 5.2.6 Glycyrrhiza glabra (L.) -- 5.2.7 Camellia sinensis (Green tea) -- 5.2.8 Camptotheca

acuminata -- 5.2.9 *Leea indica* -- 5.2.10 *Ziziphus mauritiana* (Malay apple) -- 5.2.11 *Cuscuta chinensis* -- 5.3 Conclusion -- References -- Chapter 6 Nanosystems Trends in Nutraceutical Delivery -- 6.1 Introduction -- 6.2 Classification of Nutraceuticals -- 6.3 Biopharmaceutical Issues Associated with Nutraceuticals -- 6.4 Nanosystems for Delivery of Nutraceuticals -- 6.4.1 Nanoemulsions. 6.4.2 Self-Emulsifying Systems -- 6.4.3 Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 6.4.4 Liposomes -- 6.4.5 Polymeric Nanoparticles -- 6.4.6 Inorganic Nanoparticles -- 6.5 Challenges -- 6.6 Market Potential -- 6.7 Conclusion and Perspective -- References -- Chapter 7 Nanoencapsulated Systems for Delivery of Phytopharmaceuticals -- 7.1 Introduction -- 7.1.1 Nanoencapsulation Techniques in Phytopharmaceuticals -- 7.1.1.1 Physical-Chemical Techniques -- 7.1.1.2 Chemicals Techniques -- 7.1.1.3 Mechanical Techniques -- 7.1.2 Characterization of Nanoencapsulates -- 7.1.2.1 Morphological Characterization -- 7.1.2.2 Physicochemical Characterization -- 7.1.3 Nanoencapsulated Systems for Free Delivery of Phytopharmaceuticals -- 7.1.4 Studies to Evaluate Phytopharmaceuticals Nanoencapsulates -- 7.2 Conclusions -- References -- Chapter 8 Topical Drug Delivery Using Liposomes and Liquid Crystalline Phases for Skin Cancer Therapy -- 8.1 Introduction -- 8.2 Liposomes for Topical Application -- 8.2.1 Development of Liposomal Nanoparticles -- 8.3 Liquid Crystals and Liquid Crystalline Nanodispersions for Topical Application -- 8.3.1 Characterization Techniques -- 8.4 Physical Methods Applied to Nanoparticles Delivery -- 8.4.1 Sonophoresis -- 8.4.2 Microneedles -- 8.5 Conclusions and Perspectives -- Acknowledgements -- References -- Chapter 9 Vesicular Drug Delivery in Arthritis Treatment -- 9.1 Introduction -- 9.2 Skin Penetration Pathways -- 9.2.1 Intercellular Pathway -- 9.2.2 Transcellular Pathway -- 9.2.3 Appendgeal Pathway -- 9.3 Principles of Drug Permeation Through Skin -- 9.4 Problems Associated with Conventional Dosage Forms -- 9.5 Novel Treatment Strategies for Arthritis -- 9.5.1 Traditional Liposomes as Skin Drug Delivery Systems -- 9.5.2 Transfersomes (Ultradeformable Liposomes) as Skin Drug Delivery Systems. 9.5.3 Ethosomes as Skin Drug Delivery Systems -- 9.5.4 Niosomes as Skin Drug Delivery Systems -- 9.6 Conclusion and Future Perspectives -- References -- Chapter 10 Perspectives of Novel Drug Delivery in Mycoses -- 10.1 Introduction -- 10.2 Role of Conventional Drugs in Antifungal Therapy -- 10.3 Mechanism of Action of Conventional Antifungals -- 10.4 Summary of Nanoparticles and Their Role in Antifungal Therapy -- 10.4.1 Lipid Nanoparticles -- 10.4.2 Liposome -- 10.4.3 Transfersomes -- 10.4.4 Tranethosomes -- 10.4.5 Solid Lipid Nanoparticles (SLN) -- 10.4.6 Nanostructured Lipid Carriers (NLC) -- 10.4.7 Polymer Lipid Hybrid Nanoparticles (PLN) -- 10.4.8 Polymeric Nanoparticles -- 10.4.9 Microsponge and Nanosponge Systems -- 10.4.10 Polymeric Micelles -- 10.4.11 Polymersomes -- 10.4.12 Dendrimers -- 10.4.13 Metallic Nanoparticles -- 10.5 Other Drug Delivery Systems -- 10.5.1 Niosomes -- 10.5.2 Spanlastics -- 10.5.3 Microemulsions and Nanoemulsions -- 10.5.4 Silicon Dioxide Nanoparticles -- 10.6 Conclusion -- References -- Chapter 11 Nano-Based Drug Delivery in Eliminating Tuberculosis -- 11.1 Introduction -- 11.1.1 Latent and Active Tuberculosis -- 11.1.2 Multidrug-Resistant Tuberculosis (MDR-TB) -- 11.1.3 Extensively Drug-Resistant TB -- 11.2 Antitubercular Therapy -- 11.3 Therapies Based on Nanotechnology -- 11.3.1 Nanoparticles for Anti-TB Therapy -- 11.3.2 Advantages and Disadvantages of Nanoparticles -- 11.3.3 Types of Nanoparticles and Their Characteristics -- 11.3.3.1 TB Dendrimers --

11.3.3.2 Cyclodextrins -- 11.3.3.3 Polymeric Micelles -- 11.3.3.4 Liposomes -- 11.3.3.5 Nanoemulsions -- 11.3.3.6 Solid Lipid Nanoparticles -- 11.3.3.7 Niosomes -- 11.3.3.8 Polymeric Nanoparticles -- 11.4 Routes of Administration of Nanoparticles -- 11.4.1 Oral Administration of Nanoparticles -- 11.4.2 Inhalational Administration of Nanoparticles. 11.4.3 Intravenous Administration of Nanoparticles.

Sommario/riassunto

ADVANCES in NOVEL FORMULATIONS for DRUG DELIVERY The 27 chapters describe novel strategies for drug/nutraceutical delivery and embrace the development of formulations with herbal ingredients, while also highlighting disease therapeutics. Drug delivery technology has witnessed many advancements purported to cater to the customized needs of its ultimate beneficiaries-the patients. Today, dosage forms are not confined to conventional tablets, capsules, or injectables, but have evolved to cover novel drug carriers such as particulates, vesicles, and many others. Nanotechnological advancements have played a major role in this paradigm shift in ways of delivering active pharmaceutical ingredients. A new dimension in the use of food as medicine has also gained prominence in recent years. A portmanteau of nutrition and pharmaceuticals is "nutraceuticals, " also known as functional foods and dietary supplements. The technologies which were earlier included in drug delivery have been attempted for the delivery of nutraceuticals as well. Herbal actives have received increased attention due to their low risk-to-benefit ratio. The field of drug delivery is quite dynamic in nature, as witnessed by its evolution from conventional dosage forms to nanotechnology-assisted drug products. A variety of formulations via different drug delivery routes have been developed to treat/cure/mitigate diseases or disorders. This book, comprising of 27 chapters, is a thorough compilation of information relevant to drug delivery systems with an emphasis on products based on nanotechnology. Audience Researchers, scientists, industry professionals, formulators and product developers, regulatory agencies in a variety of settings including novel drug delivery research laboratories, pharmaceutical, and pharmacy industries, biomedical sciences, food and nutraceuticals manufacturers, and nanotechnology.